Related Experiment Video
Updated: Jun 2, 2026
12:28
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
Pathological staging of frontotemporal lobar degeneration
Jillian J Kril1, Glenda M Halliday
1Discipline of Medicine, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
Journal of Molecular Neuroscience : MN
|May 10, 2011
Summary
A new staging scheme for frontotemporal lobar degeneration (FTLD) correlates temporal lobe atrophy with disease progression. This method predicts survival and differentiates FTLD subtypes, revealing neuronal loss and glial apoptosis as key pathological markers.
Area of Science:
- Neuropathology
- Neurodegenerative Diseases
- Clinical Neurology
Background:
- Frontotemporal lobar degeneration (FTLD) exhibits significant postmortem variability.
- Temporal lobe atrophy shows a linear relationship with disease progression in FTLD.
Purpose of the Study:
- To develop and review a staging scheme for FTLD pathology based on atrophy.
- To assess the clinical utility of this staging scheme in predicting survival and differentiating FTLD subtypes.
- To investigate the relationship between pathological features and disease stage.
Main Methods:
- Development of a staging scheme for FTLD pathology.
- Correlation of staging with clinical presentations (semantic dementia, behavioral variants, motor neuron disease, progressive supranuclear palsy).
- Analysis of postmortem neuropathological features (neuronal loss, astrocytosis, microvacuolation, glial apoptosis, protein deposition) in relation to disease stage.
Main Results:
- The staging scheme effectively relates to atrophy and accounts for variability.
- Temporal lobe atrophy is the most linear correlate of disease stage.
- The staging scheme is a strong predictor of survival and discriminates between semantic dementia and behavioral phenocopies.
- Patients with motor neuron disease or progressive supranuclear palsy present with significantly lower disease stages.
- No significant difference in stage distribution exists across pathological FTLD subtypes.
- Increasing neuronal loss, astrocytosis, microvacuolation, and glial apoptosis correlate with higher disease stages.
- Protein deposition does not correlate with disease stage.
Conclusions:
- The developed staging scheme provides a reliable measure of FTLD progression.
- Clinical application of the staging scheme aids in prognosis and differential diagnosis.
- The underlying disease process in FTLD appears similar across pathological subtypes.
- Cellular changes, particularly neuronal loss and glial apoptosis, are key determinants of disease stage, while protein deposition is not.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...